Trial Profile
Long-acting Exenatide: a Tool to Stop Cognitive Decline in Dysglycemic Patients With Mild Cognitive Impairment?
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Mild cognitive impairment; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DRINN
- 10 Aug 2021 Planned End Date changed from 31 Oct 2019 to 31 Oct 2021.
- 10 Aug 2021 Status changed from recruiting to active, no longer recruiting.
- 19 Aug 2019 Planned End Date changed from 1 Jul 2018 to 31 Oct 2019.